SEC Tracker
Get the app

Silexion Therapeutics SLXN

Silexion Therapeutics to hold meeting

Proxy statement

Form
DEF 14A
Filed
Importance
Routine
  1. Meeting on Oct 19, 2026
  2. Proposing share capital increase by 500M shares
  3. Proposing reverse share split ratio 1-for-15 to 1-for-25

Written from the DEF 14A on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Silexion Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Acumen Pharmaceuticals ABOS public float $45M, Jun 30, 2025
  2. Alpha Cognition ACOG public float $149M, Jun 30, 2025
  3. Adaptimmune Therapeutics ADAP
  4. Adma Biologics ADMA public float $4.2B, Jun 30, 2025
  5. Adaptive Biotechnologies ADPT public float $1.4B, Jun 30, 2025